| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.007 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.15 | 0.008 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.11 | 0.008 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.099 | 0.008 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.009 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.15 | 0.01 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |